Država: Sjedinjene Američke Države
Jezik: engleski
Izvor: NLM (National Library of Medicine)
PIPERACILLIN SODIUM (UNII: M98T69Q7HP) (PIPERACILLIN ANHYDROUS - UNII:9I628532GX), TAZOBACTAM SODIUM (UNII: UXA545ABTT) (TAZOBACTAM - UNII:SE10G96M8W)
Xellia Pharmaceuticals USA LLC
INTRAVENOUS
PRESCRIPTION DRUG
Piperacillin and Tazobactam for Injection is indicated in adults and pediatric patients (2 months of age and older) for the treatment of appendicitis (complicated by rupture or abscess) and peritonitis caused by beta-lactamase producing isolates of Escherichia coli or the following members of the Bacteroides fragilis group: B. fragilis , B. ovatus , B. thetaiotaomicron , or B. vulgatus . Piperacillin and Tazobactam for Injection is indicated in adults and pediatric patients (2 months of age and older) for the treatment of nosocomial pneumonia (moderate to severe) caused by beta-lactamase producing isolates of Staphylococcus aureus and by piperacillin/tazobactam-susceptible Acinetobacter baumannii , Haemophilus influenzae , Klebsiella pneumoniae , and Pseudomonas aeruginosa (Nosocomial pneumonia caused by P. aeruginosa should be treated in combination with an aminoglycoside) [see Dosage and Administration (2)] . Piperacillin and Tazobactam for Injection is indicated in adults for the treatment of uncompli
Piperacillin and Tazobactam for Injection, USP are supplied as follows: Storage Conditions Piperacillin and Tazobactam for Injection, USP vials should be stored at controlled room temperature (20°C to 25°C [68°F to 77°F]) prior to reconstitution. Sterile, Nonpyrogenic, Preservative-free. The container closure is not made with natural rubber latex.
Abbreviated New Drug Application
PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM- PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM INJECTION, POWDER, FOR SOLUTION XELLIA PHARMACEUTICALS USA LLC ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE PIPERACILLIN AND TAZOBACTAM FOR INJECTION SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR PIPERACILLIN AND TAZOBACTAM FOR INJECTION. PIPERACILLIN AND TAZOBACTAM FOR INJECTION, FOR INTRAVENOUS USE INITIAL U.S. APPROVAL: 1993 RECENT MAJOR CHANGES Dosage and Administration (2) 8/2021 Warnings and Precautions, Hemophagocytic Lymphohistiocytosis (5.3) 4/2022 INDICATIONS AND USAGE Piperacillin and Tazobactam for Injection is a combination of piperacillin, a penicillin-class antibacterial and tazobactam, a beta-lactamase inhibitor, indicated for the treatment of: Intra-abdominal infections in adult and pediatric patients 2 months of age and older (1.1) Nosocomial pneumonia in adult and pediatric patients 2 months of age and older (1.2) Skin and skin structure infections in adults (1.3) Female pelvic infections in adults (1.4) Community-acquired pneumonia in adults (1.5) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Piperacillin and Tazobactam for Injection and other antibacterial drugs, Piperacillin and Tazobactam for Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. (1.6) DOSAGE AND ADMINISTRATION _Adult Patients With Indications Other Than Nosocomial Pneumonia:_ The usual daily dosage of piperacillin and tazobactam for injection for adults is 3.375 g every six hours totaling 13.5 g (12 g piperacillin/1.5 g tazobactam). (2.2) _Adult Patients with Nosocomial Pneumonia_: Initial presumptive treatment of patients with nosocomial pneumonia should start with piperacillin and tazobactam for injection at a dosage of 4.5 g every six hours plus an aminoglycoside, totaling 18 g (16 g piperacillin/2 g tazobactam). (2.3) _Adult Patients with Rena Pročitajte cijeli dokument